Multidisciplinary diagnosis and treatment of advanced metastatic prostate cancer: a case report / 中华泌尿外科杂志

ABSTRACT

We reported an advanced prostate cancer patient underwent muti-disciplinary treatment with long time survival. After 18 months of androgen deprive therapy, the disease progressed to metastatic castration-resistant prostate cancer(mCRPC) stage. So enzalutamide was added and combined with radiotherapy for bone metastases, which achieved excellent survival benefits. From the diagnosis to September 2021, the patients survived for 97 months, including 79 months in the mCRPC stage. the tumor related symptoms disappeared, the PSA remained < 0.003ng/ml, and the imaging lesions remained stable.